(NASDAQ: BDSX) Biodesix's forecast annual revenue growth rate of 22.42% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.43%, and it is also forecast to beat the US market's average forecast revenue growth rate of 17.24%.
Biodesix's revenue in 2026 is $88,499,000.On average, 7 Wall Street analysts forecast BDSX's revenue for 2026 to be $1,092,798,984, with the lowest BDSX revenue forecast at $1,040,549,687, and the highest BDSX revenue forecast at $1,129,373,492. On average, 7 Wall Street analysts forecast BDSX's revenue for 2027 to be $1,302,091,925, with the lowest BDSX revenue forecast at $1,236,632,428, and the highest BDSX revenue forecast at $1,351,876,633.
In 2028, BDSX is forecast to generate $1,529,425,660 in revenue, with the lowest revenue forecast at $1,447,206,954 and the highest revenue forecast at $1,598,236,999.